莫德纳(MRNA)和默沙东(MRK)的癌症疫苗显示出进展

凤凰网港股2023-04-17

莫德纳(MRNA)和默沙东(MRK)近日在美国癌症研究协会年会上表示，皮肤癌中晚期患者，在接受莫德纳基于mRNA的癌症疫苗与默沙东的重点免疫药物Keytruda的组合疗法后，约有79%在18个月后未复发，而仅接受默沙东的Keytruda治疗的的患者有62%未复发。同时，在实验过程中，疫苗的副作用通常较轻，例如会出现疲劳等反应。据悉，Keytruda是目前非常常用的黑色素瘤辅助疗法，可以降低癌症复发风险。而mRNA疫苗可根据每个患者的癌细胞特征提供个性化治疗，对以往未获得有效治疗的患者有望提供新的治疗机会。值得注意的是，这类癌症疫苗并非是传统意义中的预防性疫苗，而是治疗性疫苗。如果这类疫苗成功问世，此疗法将扩展到更多其他癌症类别。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2328407664?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2023-04-17 10:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2328407664","market":"hk","top_or_hot":-1,"title":"莫德纳(MRNA)和默沙东(MRK)的癌症疫苗显示出进展","media":"凤凰网港股","content":"<html><body><p>莫德纳(MRNA)和<a href=\"https://laohu8.com/S/MRK\">默沙东</a>(MRK)近日在美国癌症研究协会年会上表示，皮肤癌中晚期患者，在接受莫德纳基于mRNA的癌症疫苗与默沙东的重点免疫药物Keytruda的组合疗法后，约有79%在18个月后未复发，而仅接受默沙东的Keytruda治疗的的患者有62%未复发。同时，在实验过程中，疫苗的副作用通常较轻，例如会出现疲劳等反应。 据悉，Keytruda是目前非常常用的黑色素瘤辅助疗法，可以降低癌症复发风险。而mRNA疫苗可根据每个患者的癌细胞特征提供个性化治疗，对以往未获得有效治疗的患者有望提供新的治疗机会。值得注意的是，这类癌症疫苗并非是传统意义中的预防性疫苗，而是治疗性疫苗。如果这类疫苗成功问世，此疗法将扩展到更多其他癌症类别。</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>莫德纳(MRNA)和默沙东(MRK)的癌症疫苗显示出进展</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n莫德纳(MRNA)和默沙东(MRK)的癌症疫苗显示出进展\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-04-17 10:45 北京时间&nbsp;&nbsp;&nbsp;<a href=http://hknews.szfuit.com/newRssInfo/feed?original_id=d8c0f8017ff9b2abc1f3581b649c8860><strong>凤凰网港股</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>莫德纳(MRNA)和默沙东(MRK)近日在美国癌症研究协会年会上表示，皮肤癌中晚期患者，在接受莫德纳基于mRNA的癌症疫苗与默沙东的重点免疫药物Keytruda的组合疗法后，约有79%在18个月后未复发，而仅接受默沙东的Keytruda治疗的的患者有62%未复发。同时，在实验过程中，疫苗的副作用通常较轻，例如会出现疲劳等反应。 据悉，Keytruda是目前非常常用的黑色素瘤辅助疗法，可以降低癌症...</p>\n\n<a href=\"http://hknews.szfuit.com/newRssInfo/feed?original_id=d8c0f8017ff9b2abc1f3581b649c8860\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2106854487.HKD","symbol_name":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","start_time":0,"source_url":"http://hknews.szfuit.com/newRssInfo/feed?original_id=d8c0f8017ff9b2abc1f3581b649c8860","article_id":"2328407664","we_media_id":"1002821290","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2328407664","pubTimestamp":1681699529,"sourceInfo":null,"weMediaInfo":{"media_name":"凤凰网港股","introduction":"凤凰网港股","home_visible":1,"id":"1002821290","head_image":"https://static.tigerbbs.com/b6fb647077f1ce46dc341fc35c26e817"},"summary":"莫德纳和默沙东近日在美国癌症研究协会年会上表示，皮肤癌中晚期患者，在接受莫德纳基于mRNA的癌症疫苗与默沙东的重点免疫药物Keytruda的组合疗法后，约有79%在18个月后未复发，而仅接受默沙东的Keytruda治疗的的患者有62%未复发。据悉，Keytruda是目前非常常用的黑色素瘤辅助疗法，可以降低癌症复发风险。而mRNA疫苗可根据每个患者的癌细胞特征提供个性化治疗，对以往未获得有效治疗的患者有望提供新的治疗机会。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159646":"疫苗","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU2023250843.SGD":"Allianz Thematica Cl AT Acc H2-SGD","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","MRNA":"Moderna, Inc.","SG9999002232.USD":"Allianz Global High Payout USD","BK4548":"巴美列捷福持仓","LU0234572021.USD":"高盛美国核心股票组合Acc","SG9999014559.SGD":"United Income Focus Trust Dis SGD","BK4516":"特朗普概念","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","BK4532":"文艺复兴科技持仓","SG9999014567.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USD) ACC","LU0861579265.USD":"联博低波幅策略股票基金A","BK4585":"ETF&股票定投概念","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU0122379950.USD":"贝莱德世界健康科学A2","BK4139":"生物科技","SG9999015358.SGD":"United Income Focus Trust Dis SGD-H","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","SG9999014542.SGD":"United Income Focus Trust Acc SGD","SG9999001176.USD":"United Global Healthcare Acc USD","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","BK4559":"巴菲特持仓","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","BK4501":"段永平概念","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","BK4588":"碎股","LU1917777945.USD":"安联专题基金Cl AT Acc","BK4550":"红杉资本持仓","SG9999014575.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USDHDG) INC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","BK4568":"美国抗疫概念","MRK":"默沙东","BK4551":"寇图资本持仓"},"translate_title":"Cancer vaccines from Moderna (MRNA) and Merck (MRK) show progress","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159646":1,"MRNA":1,"MRK":1},"content_text":"莫德纳(MRNA)和默沙东(MRK)近日在美国癌症研究协会年会上表示，皮肤癌中晚期患者，在接受莫德纳基于mRNA的癌症疫苗与默沙东的重点免疫药物Keytruda的组合疗法后，约有79%在18个月后未复发，而仅接受默沙东的Keytruda治疗的的患者有62%未复发。同时，在实验过程中，疫苗的副作用通常较轻，例如会出现疲劳等反应。 据悉，Keytruda是目前非常常用的黑色素瘤辅助疗法，可以降低癌症复发风险。而mRNA疫苗可根据每个患者的癌细胞特征提供个性化治疗，对以往未获得有效治疗的患者有望提供新的治疗机会。值得注意的是，这类癌症疫苗并非是传统意义中的预防性疫苗，而是治疗性疫苗。如果这类疫苗成功问世，此疗法将扩展到更多其他癌症类别。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"claudebot","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2328407664"}